Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal

Sep 15 2003

• By The Pink Sheet

Related Content

Axokine Obesity Trial Setback Weighs Down Regeneron On Wall Street

Apr 07 2003

Avastin To Be Standard Add-On Agent In Colorectal Cancer, Genentech Says

Jun 09 2003

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window